Drug Development Research,
Journal Year:
2024,
Volume and Issue:
85(2)
Published: April 1, 2024
Abstract
Icaritin
is
a
natural
prenylated
flavonoid
derived
from
the
Chinese
herb
Epimedium.
The
compound
has
shown
antitumor
effects
in
various
cancers,
especially
hepatocellular
carcinoma
(HCC).
exerts
its
anticancer
activity
by
modulating
multiple
signaling
pathways,
such
as
IL‐6/JAK/STAT3,
ER‐α36,
and
NF‐κB,
affecting
tumor
microenvironment
immune
system.
Several
clinical
trials
have
evaluated
safety
efficacy
of
icaritin
advanced
HCC
patients
with
poor
prognoses,
who
are
unsuitable
for
conventional
therapies.
results
demonstrated
that
can
improve
survival,
delay
progression,
produce
benefits
these
patients,
favorable
profile
minimal
adverse
events.
Moreover,
enhance
response
regulating
function
phenotype
cells,
CD8+
T
MDSCs,
neutrophils,
macrophages.
These
findings
suggest
promising
candidate
immunotherapy
other
cancers.
However,
further
studies
needed
to
elucidate
molecular
mechanisms
optimal
dosing
regimens
potential
synergistic
agents.
Therefore,
this
comprehensive
review
scientific
literature
aims
summarize
advances
knowledge
preclinical
well
pharmacokinetic,
metabolism,
toxicity,
action
recognize
main
challenge,
gaps,
opportunities
develop
medication
cancer
use.
Thus,
our
objective
was
clarify
current
state
use
an
drug.
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(11), P. 1642 - 1642
Published: May 27, 2024
Liver
cancer
ranks
third
globally
among
causes
of
cancer-related
deaths,
posing
a
significant
public
health
challenge.
However,
current
treatments
are
inadequate,
prompting
growing
demand
for
novel,
safe,
and
effective
therapies.
Natural
products
(NPs)
have
emerged
as
promising
candidates
in
drug
development
due
to
their
diverse
biological
activities,
low
toxicity,
minimal
side
effects.
This
paper
begins
by
reviewing
existing
treatment
methods
drugs
liver
cancer.
It
then
summarizes
the
therapeutic
effects
NPs
sourced
from
various
origins
on
Finally,
we
analyze
potential
mechanisms
treating
cancer,
including
inhibition
angiogenesis,
migration,
invasion;
regulation
cell
cycle;
induction
apoptosis,
autophagy,
pyroptosis,
ferroptosis;
influence
tumor
metabolism;
immune
regulation;
intestinal
function;
key
signaling
pathways.
systematic
review
aims
provide
comprehensive
overview
research
treatment,
offering
foundation
further
application
pharmaceuticals
functional
foods.
International Journal of Nanomedicine,
Journal Year:
2024,
Volume and Issue:
Volume 19, P. 3461 - 3473
Published: April 1, 2024
Purpose:
Ivosidenib
(IVO),
an
isocitrate
dehydrogenase-1
(IDH1)
used
for
treatment
of
acute
myeloid
leukemia
(AML)
and
cholangiocarcinoma.However,
poor
solubility,
low
bioavailability,
high
dose
side
effects
limit
clinical
application
IVO.Methods:
Ivosidenib-loaded
PLGA
nanoparticles
(IVO-PLGA-NPs)
chitosan
coated
(IVO-CS-PLGA-NPs)
were
prepared
using
emulsification
solvent
evaporation
method
the
liver
cancer.
Results:The
developed
IVO-PLGA-NPs
evaluated
their
particle
size
(171.7±4.9
nm),
PDI
(0.333),
ZP
(-23.0±5.8
mV),
EE
(96.3±4.3%),
DL
(9.66±1.1%);similarly,
IVO-CS-PLGA-NPs
(177.3±5.2
(0.311),
+25.9±5.7
mV,
(90.8±5.7%),
(9.42±0.7%).The
coating
was
evidenced
by
increase
in
mean
positive
value.Because
coating,
showed
a
more
stable
prolonged
release
IVO
than
IVO-PLGA-NPs.In
comparison
to
pure-IVO,
found
be
effective
against
HepG2
cells,
with
IC
50
values
MTT
assay
being
approximately
half
those
pure-IVO.In
expressions
caspase-3,
caspase-9,
p53
significantly
(p
<
0.05)
elevated.Conclusion:
Overall,
these
findings
suggest
that
improves
delivery
efficacy
ivosidenib
cancer
treatment.
Journal of Asian Natural Products Research,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 13
Published: Feb. 22, 2025
Esculetin
is
a
coumarin
compound
with
anticancer,
antioxidant,
and
anti-inflammatory
activities.
In
this
study,
we
synthesized
an
esculetin
derivative,
6,7-bis(Pentyloxy)-2H-Chromen-2-One
(BPCO),
through
etherification.
BPCO
inhibited
the
proliferation
of
HepG2
cells
in
dose-
time-dependent
manner.
It
also
cell
migration,
promoted
apoptosis,
caused
cycle
arrest
at
G1
phase.
Additionally,
downregulated
expression
levels
Bcl-2
Bcl-XL
upregulated
Bax
Bak.
This
study
shows
that
inhibits
hepatocellular
carcinoma
induces
providing
basis
for
further
as
antitumor
agent.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(12), P. 10354 - 10354
Published: June 19, 2023
There
is
no
doubt
that
significant
progress
has
been
made
in
tumor
therapy
the
past
decades.
However,
discovery
of
new
molecules
with
potential
antitumor
properties
still
remains
one
most
challenges
field
anticancer
therapy.
Nature,
especially
plants,
a
rich
source
phytochemicals
pleiotropic
biological
activities.
Among
plethora
phytochemicals,
chalcones,
bioprecursors
flavonoid
and
isoflavonoids
synthesis
higher
have
attracted
attention
due
to
broad
spectrum
activities
clinical
applications.
Regarding
antiproliferative
effects
multiple
mechanisms
action
including
cell
cycle
arrest,
induction
different
forms
death
modulation
various
signaling
pathways
documented.
This
review
summarizes
current
knowledge
related
natural
chalcones
types
malignancies
breast
cancers,
cancers
gastrointestinal
tract,
lung
renal
bladder
melanoma.
Frontiers in Pharmacology,
Journal Year:
2023,
Volume and Issue:
14
Published: March 21, 2023
Primary
liver
cancer
is
the
second
leading
cause
of
tumor-related
deaths
in
China,
with
hepatocellular
carcinoma
(HCC)
accounting
for
80%–90%
these.
Since
there
a
lack
symptoms
early
stages
HCC,
large
proportion
patients
were
identified
unresectable
HCC
when
diagnosed.
Due
to
severe
resistance
chemotherapy,
advanced
traditionally
treated
systematic
therapy
past
decades,
and
tyrosine
kinase
inhibitor
(TKI)
sorafenib
has
remained
only
treatment
option
since
2008.
Immunotherapies,
particularly
immune
checkpoint
inhibitors
(ICIs),
have
shown
strong
anti-tumor
effect
been
supported
by
several
guidelines
recently.
ICIs,
example
programmed
cell
death-1
(PD-1)
such
as
nivolumab
pembrolizumab,
death
ligand
1
(PD-L1)
atezolizumab,
cytotoxic
T-lymphocyte-associated
protein
4
(CTLA-4)
ipilimumab,
ICI-based
combination
TKIs,
VEGF-neutralizing
antibody
or
local
therapies,
are
being
further
studied
clinical
trials.
However,
immune-related
adverse
events
(irAEs)
including
cutaneous
toxicity,
gastrointestinal
hepatotoxicity
may
lead
termination
ICI
even
threaten
patients’
lives.
This
review
aims
summarize
currently
available
immunotherapies
introduce
irAEs
their
managements
order
provide
references
application
research.
Frontiers in Oncology,
Journal Year:
2022,
Volume and Issue:
11
Published: Jan. 26, 2022
Liver
cancer
is
the
third
most
common
cause
of
cancer-related
death
following
lung
and
stomach
cancers.
As
a
highly
lethal
disease,
liver
diagnosed
frequently
in
less
developed
countries.
Natural
compounds
extracted
from
herbs,
animals
natural
materials
have
been
adopted
by
traditional
Chinese
medicine
(TCM)
practices
reported
to
be
effective
development
new
medications
for
treatment
diseases.
It
important
focus
on
mechanisms
action
against
hepatocellular
carcinoma
(HCC),
particularly
terms
cell
cycle
regulation,
apoptosis
induction,
autophagy
mediation
migration
invasion.
In
this
review,
we
characterize
novel
representative
according
their
pharmacologic
effects
based
recently
published
studies.
The
aim
review
summarize
explore
therapeutic
drug
targets
compounds,
which
could
accelerate
discovery
anticancer
drugs.